Expanding Clinical Laboratory Tobacco Product Evaluation Methods to Loose-leaf Tobacco Vaporizers

Overview

Journal Drug Alcohol Depend

Publisher Elsevier

Specialty Psychiatry

Date 2016 Oct 22

PMID 27768968

Citations 15

Authors

Alexa A Lopez

Marzena Hiler

Sarah Maloney

Thomas Eissenberg

Alison B Breland

Affiliations

Soon will be listed here.

Abstract

Background: Novel tobacco products entering the US market include electronic cigarettes (ECIGs) and products advertised to "heat, not burn" tobacco. There is a growing literature regarding the acute effects of ECIGs. Less is known about "heat, not burn" products. This study's purpose was to expand existing clinical laboratory methods to examine, in cigarette smokers, the acute effects of a "heat, not burn" "loose-leaf tobacco vaporizer" (LLTV).

Methods: Plasma nicotine and breath carbon monoxide (CO) concentration and tobacco abstinence symptom severity were measured before and after two 10-puff (30-s interpuff interval) product use bouts separated by 60min. LLTV effects were compared to participants' own brand (OB) cigarettes and an ECIG (3.3V; 1.5ohm; 18mg/ml nicotine).

Results: Relative to OB, LLTV increased plasma nicotine concentration to a lesser degree, did not increase CO, and did not appear to reduce abstinence symptoms as effectively. Relative to ECIG, LLTV nicotine and CO delivery and abstinence symptom suppression did not differ. Participants reported that both the LLTV and ECIG were significantly less satisfying than OB.

Conclusions: Results demonstrate that LLTVs are capable of delivering nicotine and suppressing tobacco abstinence symptoms partially; acute effects of these products can be evaluated using existing clinical laboratory methods. Results can inform tobacco product regulation and may be predictive of the extent that these products have the potential to benefit or harm overall public health.

Citing Articles

Assessment of human abuse potential of an unflavored, sucralose-sweetened electronic cigarette in combustible cigarette smokers.

Maloney S, Hoetger C, Bono R, Lester Scholtes R, Combs M, Karaoghlanian N Exp Clin Psychopharmacol. 2024; 32(5):588-603.

PMID: 38815111 PMC: 11870153. DOI: 10.1037/pha0000720.

Critical appraisal of interventional clinical trials assessing heated tobacco products: a systematic review.

Braznell S, van den Akker A, Metcalfe C, Taylor G, Hartmann-Boyce J Tob Control. 2022; 33(3):383-394.

PMID: 36347620 PMC: 11041615. DOI: 10.1136/tc-2022-057522.

'It's like if a vape pen and a cigarette had a baby': a mixed methods study of perceptions and use of IQOS among US young adults.

Duan Z, Le D, Ciceron A, Dickey-Chasins R, Wysota C, Bar-Zeev Y Health Educ Res. 2022; 37(5):364-377.

PMID: 36036655 PMC: 9502850. DOI: 10.1093/her/cyac019.

"It's Like Jogging Next to the Highway": A Qualitative Analysis of the Motivations and Experiences of Single-, Dual-, and Ex-Users of IQOS in The Netherlands.

Havermans A, van Nierop L, Pauwels C, Talhout R Toxics. 2022; 10(6).

PMID: 35736892 PMC: 9229017. DOI: 10.3390/toxics10060283.

Exposure to Heated Tobacco Products and Adverse Health Effects, a Systematic Review.

Znyk M, Jurewicz J, Kaleta D Int J Environ Res Public Health. 2021; 18(12).

PMID: 34205612 PMC: 8296358. DOI: 10.3390/ijerph18126651.

References

Lopez A, Hiler M, Soule E, Ramoa C, Karaoghlanian N, Lipato T . Effects of Electronic Cigarette Liquid Nicotine Concentration on Plasma Nicotine and Puff Topography in Tobacco Cigarette Smokers: A Preliminary Report. Nicotine Tob Res. 2015; 18(5):720-3. PMC: 5896822. DOI: 10.1093/ntr/ntv182. View

Cobb C, Blank M, Morlett A, Shihadeh A, Jaroudi E, Karaoghlanian N . Comparison of puff topography, toxicant exposure, and subjective effects in low- and high-frequency waterpipe users: a double-blind, placebo-control study. Nicotine Tob Res. 2014; 17(6):667-74. PMC: 4838047. DOI: 10.1093/ntr/ntu196. View

Pickworth W, Bunker E, Henningfield J . Transdermal nicotine: reduction of smoking with minimal abuse liability. Psychopharmacology (Berl). 1994; 115(1-2):9-14. DOI: 10.1007/BF02244745. View

Hecht S, Carmella S, Kotandeniya D, Pillsbury M, Chen M, Ransom B . Evaluation of toxicant and carcinogen metabolites in the urine of e-cigarette users versus cigarette smokers. Nicotine Tob Res. 2014; 17(6):704-9. PMC: 4481723. DOI: 10.1093/ntr/ntu218. View

Hughes J, Keely J, Callas P . Ever users versus never users of a "less risky" cigarette. Psychol Addict Behav. 2005; 19(4):439-42. DOI: 10.1037/0893-164X.19.4.439. View

Ramoa C, Hiler M, Spindle T, Lopez A, Karaoghlanian N, Lipato T . Electronic cigarette nicotine delivery can exceed that of combustible cigarettes: a preliminary report. Tob Control. 2015; 25(e1):e6-9. PMC: 4888876. DOI: 10.1136/tobaccocontrol-2015-052447. View

Farsalinos K, Spyrou A, Stefopoulos C, Tsimopoulou K, Kourkoveli P, Tsiapras D . Nicotine absorption from electronic cigarette use: comparison between experienced consumers (vapers) and naïve users (smokers). Sci Rep. 2015; 5:11269. PMC: 4469966. DOI: 10.1038/srep11269. View

Cox L, Tiffany S, Christen A . Evaluation of the brief questionnaire of smoking urges (QSU-brief) in laboratory and clinical settings. Nicotine Tob Res. 2001; 3(1):7-16. DOI: 10.1080/14622200020032051. View

Breland A, Soule E, Lopez A, Ramoa C, El-Hellani A, Eissenberg T . Electronic cigarettes: what are they and what do they do?. Ann N Y Acad Sci. 2016; 1394(1):5-30. PMC: 4947026. DOI: 10.1111/nyas.12977. View

10.

Blank M, Cobb C, Kilgalen B, Austin J, Weaver M, Shihadeh A . Acute effects of waterpipe tobacco smoking: a double-blind, placebo-control study. Drug Alcohol Depend. 2011; 116(1-3):102-9. PMC: 3098931. DOI: 10.1016/j.drugalcdep.2010.11.026. View

11.

Hughes J, Keely J . The effect of a novel smoking system--Accord--on ongoing smoking and toxin exposure. Nicotine Tob Res. 2005; 6(6):1021-7. DOI: 10.1080/14622200412331296011. View

12.

Cobb C, Shihadeh A, Weaver M, Eissenberg T . Waterpipe tobacco smoking and cigarette smoking: a direct comparison of toxicant exposure and subjective effects. Nicotine Tob Res. 2010; 13(2):78-87. PMC: 3107609. DOI: 10.1093/ntr/ntq212. View

13.

Spindle T, Hiler M, Breland A, Karaoghlanian N, Shihadeh A, Eissenberg T . The Influence of a Mouthpiece-Based Topography Measurement Device on Electronic Cigarette User's Plasma Nicotine Concentration, Heart Rate, and Subjective Effects Under Directed and Ad Libitum Use Conditions. Nicotine Tob Res. 2016; 19(4):469-476. PMC: 6075397. DOI: 10.1093/ntr/ntw174. View

14.

Tabuchi T, Kiyohara K, Hoshino T, Bekki K, Inaba Y, Kunugita N . Awareness and use of electronic cigarettes and heat-not-burn tobacco products in Japan. Addiction. 2015; 111(4):706-13. DOI: 10.1111/add.13231. View

15.

Fagerstrom K, Hughes J, Callas P . Long-term effects of the Eclipse cigarette substitute and the nicotine inhaler in smokers not interested in quitting. Nicotine Tob Res. 2003; 4 Suppl 2:S141-5. DOI: 10.1080/1462220021000032771. View

16.

Shiffman S, Pillitteri J, Burton S, Di Marino M . Smoker and ex-smoker reactions to cigarettes claiming reduced risk. Tob Control. 2004; 13(1):78-84. PMC: 1747811. DOI: 10.1136/tc.2003.005272. View

17.

Heatherton T, Kozlowski L, Frecker R, Fagerstrom K . The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire. Br J Addict. 1991; 86(9):1119-27. DOI: 10.1111/j.1360-0443.1991.tb01879.x. View

18.

Caraballo R, Pederson L, Gupta N . New tobacco products: do smokers like them?. Tob Control. 2006; 15(1):39-44. PMC: 2563627. DOI: 10.1136/tc.2005.012856. View

19.

Spindle T, Breland A, Karaoghlanian N, Shihadeh A, Eissenberg T . Preliminary results of an examination of electronic cigarette user puff topography: the effect of a mouthpiece-based topography measurement device on plasma nicotine and subjective effects. Nicotine Tob Res. 2014; 17(2):142-9. PMC: 4838000. DOI: 10.1093/ntr/ntu186. View

20.

Fagerstrom K, Hughes J, Rasmussen T, Callas P . Randomised trial investigating effect of a novel nicotine delivery device (Eclipse) and a nicotine oral inhaler on smoking behaviour, nicotine and carbon monoxide exposure, and motivation to quit. Tob Control. 2000; 9(3):327-33. PMC: 1748373. DOI: 10.1136/tc.9.3.327. View